Literature DB >> 8004058

Viral antibodies in infectious mononucleosis.

G Haukenes1, B Viggen, B Boye, M B Kalvenes, R Flø, K H Kalland.   

Abstract

Patients with Epstein-Barr virus (EBV) infectious mononucleosis (IM) usually develop heterophilic antibodies and some autoantibodies. Antibodies to rubella, measles, adeno-, entero-, herpes simplex, cytomegalo- and varicella-zoster viruses were titrated in sera from IM patients and matched healthy controls using the complement fixation test (CFT) and the haemagglutination inhibition test. Except for herpes simplex virus and cytomegalovirus, the IM sera had significantly higher arithmetical and geometrical mean antibody titres and showed in most cases higher antibody prevalences in the CFT. The titre rise was most pronounced for rubella and measles antibodies, between 2- and 3-fold. There were no cases of very high titres occasionally seen in IM. The IM sera had higher total IgG serum levels than the controls, 17.27 g/l and 11.8 g/l, respectively (P < 0.001). The present data show that in addition to previously reported high levels of some autoantibodies and of heterophilic antibodies, there is a more general increase in IgG antibodies to commonly occurring viruses. This increase is most likely due to the polyclonal activation of B-lymphocytes following the binding of EBV to the complement receptor CR2 (CD21). When due consideration is given to the possible occasional occurrence of a false positive rubella IgM test, the raised antibody-titres will most likely not interfere with routine diagnostics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004058     DOI: 10.1111/j.1574-695X.1994.tb00446.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  6 in total

1.  Application of a commercial immunoblot to define EBV IgG seroprofiles.

Authors:  Fernando de Ory; Eulalia Guisasola; David Tarragó; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections.

Authors:  Fernando de Ory; María Eulalia Guisasola; Juan Carlos Sanz; Isabel García-Bermejo
Journal:  Clin Vaccine Immunol       Date:  2010-12-29

3.  Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers.

Authors:  D Lang; R Vornhagen; M Rothe; W Hinderer; H H Sonneborn; B Plachter
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  Wen-Chuan Hsieh; Yao Chang; Mei-Chi Hsu; Bau-Shin Lan; Guan-Chung Hsiao; Huai-Chia Chuang; Ih-Jen Su
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

5.  EBV VCA IgM and cytomegalovirus IgM dual positivity is a false positive finding related to age and hepatic involvement of primary Epstein-Barr virus infection in children.

Authors:  Min Ji Sohn; Jin Min Cho; Jin Soo Moon; Jae Sung Ko; Hye Ran Yang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  Interference of D-dimer levels from heterophilic antibody in COVID-19: A serious concern in treatment and follow-up of patients.

Authors:  Demircan Ozbalci; Duygu Kumbul Doguc; Gulruhsar Yilmaz; Onder Ozturk; Fevziye Burcu Sirin; Fusun Zeynep Akcam
Journal:  Int J Lab Hematol       Date:  2021-08-18       Impact factor: 3.450

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.